Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

New Approaches to SCLC Therapy: From the Laboratory to the Clinic.

Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, Carbone D, Chen HJ, Christensen CL, Dive C, Farago AF, Govindan R, Hann C, Hellmann MD, Horn L, Johnson JE, Ju YS, Kang S, Krasnow M, Lee J, Lee SH, Lehman J, Lok B, Lovly C, MacPherson D, McFadden D, Minna J, Oser M, Park K, Park KS, Pommier Y, Quaranta V, Ready N, Sage J, Scagliotti G, Sos ML, Sutherland KD, Travis WD, Vakoc CR, Wait SJ, Wistuba I, Wong KK, Zhang H, Daigneault J, Wiens J, Rudin CM, Oliver TG.

J Thorac Oncol. 2020 Apr;15(4):520-540. doi: 10.1016/j.jtho.2020.01.016. Epub 2020 Feb 1. Review.

PMID:
32018053
2.

CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.

Zhang H, Christensen CL, Dries R, Oser MG, Deng J, Diskin B, Li F, Pan Y, Zhang X, Yin Y, Papadopoulos E, Pyon V, Thakurdin C, Kwiatkowski N, Jani K, Rabin AR, Castro DM, Chen T, Silver H, Huang Q, Bulatovic M, Dowling CM, Sundberg B, Leggett A, Ranieri M, Han H, Li S, Yang A, Labbe KE, Almonte C, Sviderskiy VO, Quinn M, Donaghue J, Wang ES, Zhang T, He Z, Velcheti V, Hammerman PS, Freeman GJ, Bonneau R, Kaelin WG Jr, Sutherland KD, Kersbergen A, Aguirre AJ, Yuan GC, Rothenberg E, Miller G, Gray NS, Wong KK.

Cancer Cell. 2020 Jan 13;37(1):37-54.e9. doi: 10.1016/j.ccell.2019.11.003. Epub 2019 Dec 26.

PMID:
31883968
3.

Characterization of a novel human BFL-1-specific monoclonal antibody.

Gangoda L, Teh CE, Dengler MA, Best SA, Weeden CE, Tai L, Lee EF, Fairlie WD, Sutherland KD, Harrison LC, Gray DH, Strasser A, Herold MJ.

Cell Death Differ. 2020 Feb;27(2):826-828. doi: 10.1038/s41418-019-0454-y. Epub 2019 Nov 12. No abstract available.

PMID:
31719651
4.

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer.

Burr ML, Sparbier CE, Chan KL, Chan YC, Kersbergen A, Lam EYN, Azidis-Yates E, Vassiliadis D, Bell CC, Gilan O, Jackson S, Tan L, Wong SQ, Hollizeck S, Michalak EM, Siddle HV, McCabe MT, Prinjha RK, Guerra GR, Solomon BJ, Sandhu S, Dawson SJ, Beavis PA, Tothill RW, Cullinane C, Lehner PJ, Sutherland KD, Dawson MA.

Cancer Cell. 2019 Oct 14;36(4):385-401.e8. doi: 10.1016/j.ccell.2019.08.008. Epub 2019 Sep 26.

5.

Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma.

Best SA, Ding S, Kersbergen A, Dong X, Song JY, Xie Y, Reljic B, Li K, Vince JE, Rathi V, Wright GM, Ritchie ME, Sutherland KD.

Nat Commun. 2019 Sep 13;10(1):4190. doi: 10.1038/s41467-019-12164-y.

6.

Lung morphogenesis is orchestrated through Grainyhead-like 2 (Grhl2) transcriptional programs.

Kersbergen A, Best SA, Dworkin S, Ah-Cann C, de Vries ME, Asselin-Labat ML, Ritchie ME, Jane SM, Sutherland KD.

Dev Biol. 2018 Nov 1;443(1):1-9. doi: 10.1016/j.ydbio.2018.09.002. Epub 2018 Sep 5.

7.

"Keaping" a lid on lung cancer: the Keap1-Nrf2 pathway.

Best SA, Sutherland KD.

Cell Cycle. 2018;17(14):1696-1707. doi: 10.1080/15384101.2018.1496756. Epub 2018 Aug 1. Review.

8.

FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium.

Best SA, Harapas CR, Kersbergen A, Rathi V, Asselin-Labat ML, Sutherland KD.

Oncogene. 2018 Nov;37(46):6096-6104. doi: 10.1038/s41388-018-0399-5. Epub 2018 Jul 10.

9.

Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.

Best SA, De Souza DP, Kersbergen A, Policheni AN, Dayalan S, Tull D, Rathi V, Gray DH, Ritchie ME, McConville MJ, Sutherland KD.

Cell Metab. 2018 Apr 3;27(4):935-943.e4. doi: 10.1016/j.cmet.2018.02.006. Epub 2018 Mar 8.

10.

Combining Cell Type-Restricted Adenoviral Targeting with Immunostaining and Flow Cytometry to Identify Cells-of-Origin of Lung Cancer.

Best SA, Kersbergen A, Asselin-Labat ML, Sutherland KD.

Methods Mol Biol. 2018;1725:15-29. doi: 10.1007/978-1-4939-7568-6_2.

PMID:
29322405
11.

Lung Basal Stem Cells Rapidly Repair DNA Damage Using the Error-Prone Nonhomologous End-Joining Pathway.

Weeden CE, Chen Y, Ma SB, Hu Y, Ramm G, Sutherland KD, Smyth GK, Asselin-Labat ML.

PLoS Biol. 2017 Jan 26;15(1):e2000731. doi: 10.1371/journal.pbio.2000731. eCollection 2017 Jan.

12.

SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin.

Ferone G, Song JY, Sutherland KD, Bhaskaran R, Monkhorst K, Lambooij JP, Proost N, Gargiulo G, Berns A.

Cancer Cell. 2016 Oct 10;30(4):519-532. doi: 10.1016/j.ccell.2016.09.001.

13.

Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.

Serresi M, Gargiulo G, Proost N, Siteur B, Cesaroni M, Koppens M, Xie H, Sutherland KD, Hulsman D, Citterio E, Orkin S, Berns A, van Lohuizen M.

Cancer Cell. 2016 Jan 11;29(1):17-31. doi: 10.1016/j.ccell.2015.12.006. Erratum in: Cancer Cell. 2016 Feb 8;29(2):241.

14.

Cellular Mechanisms Underlying Intertumoral Heterogeneity.

Sutherland KD, Visvader JE.

Trends Cancer. 2015 Sep;1(1):15-23. doi: 10.1016/j.trecan.2015.07.003. Epub 2015 Sep 28. Review.

PMID:
28741558
15.

Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasis.

Kwon MC, Proost N, Song JY, Sutherland KD, Zevenhoven J, Berns A.

Genes Dev. 2015 Aug 1;29(15):1587-92. doi: 10.1101/gad.262998.115. Epub 2015 Jul 27.

16.

The LIM-domain only protein 4 contributes to lung epithelial cell proliferation but is not essential for tumor progression.

Holik AZ, Filby CE, Pasquet J, Viitaniemi K, Ciciulla J, Sutherland KD, Asselin-Labat ML.

Respir Res. 2015 Jun 7;16:67. doi: 10.1186/s12931-015-0228-0.

17.

Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma.

Sutherland KD, Song JY, Kwon MC, Proost N, Zevenhoven J, Berns A.

Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4952-7. doi: 10.1073/pnas.1319963111. Epub 2014 Feb 28.

18.

Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14.

Asselin-Labat ML, Sutherland KD, Vaillant F, Gyorki DE, Wu D, Holroyd S, Breslin K, Ward T, Shi W, Bath ML, Deb S, Fox SB, Smyth GK, Lindeman GJ, Visvader JE.

Mol Cell Biol. 2011 Nov;31(22):4609-22. doi: 10.1128/MCB.05766-11. Epub 2011 Sep 19.

19.

Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung.

Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A.

Cancer Cell. 2011 Jun 14;19(6):754-64. doi: 10.1016/j.ccr.2011.04.019.

20.

Cell of origin of lung cancer.

Sutherland KD, Berns A.

Mol Oncol. 2010 Oct;4(5):397-403. doi: 10.1016/j.molonc.2010.05.002. Epub 2010 Jun 8.

21.

Impaired lactation in mice expressing dominant-negative FADD in mammary epithelium.

Shackleton M, O'Reilly LA, Sutherland KD, Bath ML, Ellis S, Strasser A, Visvader JE, Lindeman GJ.

Dev Dyn. 2009 Apr;238(4):1010-6. doi: 10.1002/dvdy.21917.

22.

Knocking off SOCS genes in the mammary gland.

Sutherland KD, Lindeman GJ, Visvader JE.

Cell Cycle. 2007 Apr 1;6(7):799-803. Epub 2007 Apr 20. Review.

PMID:
17377501
23.

The molecular culprits underlying precocious mammary gland involution.

Sutherland KD, Lindeman GJ, Visvader JE.

J Mammary Gland Biol Neoplasia. 2007 Mar;12(1):15-23. Review.

PMID:
17323120
24.

Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation.

Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, Hartley L, Robb L, Grosveld FG, van der Wees J, Lindeman GJ, Visvader JE.

Nat Cell Biol. 2007 Feb;9(2):201-9. Epub 2006 Dec 24.

PMID:
17187062
25.

c-myc as a mediator of accelerated apoptosis and involution in mammary glands lacking Socs3.

Sutherland KD, Vaillant F, Alexander WS, Wintermantel TM, Forrest NC, Holroyd SL, McManus EJ, Schutz G, Watson CJ, Chodosh LA, Lindeman GJ, Visvader JE.

EMBO J. 2006 Dec 13;25(24):5805-15. Epub 2006 Nov 30.

26.

Differential hypermethylation of SOCS genes in ovarian and breast carcinomas.

Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, Brentzell L, Phillips W, Campbell IG, Visvader JE.

Oncogene. 2004 Oct 7;23(46):7726-33.

PMID:
15361843
27.

SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis.

Croker BA, Metcalf D, Robb L, Wei W, Mifsud S, DiRago L, Cluse LA, Sutherland KD, Hartley L, Williams E, Zhang JG, Hilton DJ, Nicola NA, Alexander WS, Roberts AW.

Immunity. 2004 Feb;20(2):153-65.

28.

Identification of Taxreb107 as a lactogenic hormone responsive gene in mammary epithelial cells.

Wittlin S, Sutherland KD, Visvader JE, Lindeman GJ.

Biochim Biophys Acta. 2003 Oct 21;1642(3):139-47.

29.

Mutational analysis of the LMO4 gene, encoding a BRCA1-interacting protein, in breast carcinomas.

Sutherland KD, Visvader JE, Choong DY, Sum EY, Lindeman GJ, Campbell IG.

Int J Cancer. 2003 Oct 20;107(1):155-8.

30.

CPAP is a novel stat5-interacting cofactor that augments stat5-mediated transcriptional activity.

Peng B, Sutherland KD, Sum EY, Olayioye M, Wittlin S, Tang TK, Lindeman GJ, Visvader JE.

Mol Endocrinol. 2002 Sep;16(9):2019-33.

PMID:
12198240
31.

Denture patients: psychological evaluation and preparation.

Sutherland KD.

TIC. 1984 Jan;43(1):1-5. No abstract available.

PMID:
6583875
32.

Denture patients: psychological evaluation and preparation.

Sutherland KD.

TIC. 1970 Jul;29(7):1-5. No abstract available.

PMID:
5269605
33.
35.

Far western retirement living and investing. 1.

Sutherland KD.

Dent Econ. 1969 Jan;59(1):31-5. No abstract available.

PMID:
5248547
36.

Planning for present recreation...future retirement.

Sutherland KD.

Dent Econ. 1968 Jul;58(7):27-32. No abstract available.

PMID:
5243473
37.

The bond market demands your investigation.

Sutherland KD.

Dent Econ. 1968 Jun;58(6):62-3 passim. No abstract available.

PMID:
5241984
38.

A further consideration of convertible bonds. II.

Sutherland KD.

Oral Hyg. 1967 Dec;57(12):68-70 passim. No abstract available.

PMID:
5238185
39.

A further consideration of convertible bonds. I.

Sutherland KD.

Oral Hyg. 1967 Oct;57(10):34-5 passim. No abstract available.

PMID:
5236838
40.

The dentist builds a personal investment fund.

Sutherland KD.

Oral Hyg. 1967 Aug;57(8):27-31. No abstract available.

PMID:
5230758
41.

Your employees need planning not unionization.

Sutherland KD.

Oral Hyg. 1967 May;57(5):58-60 passim. No abstract available.

PMID:
5228454
42.

Convertible bonds...the dual-purpose investment.

Sutherland KD.

Oral Hyg. 1967 Apr;57(4):27-31. No abstract available.

PMID:
5230745
43.

The dental hygienist's value...in dollars and "sense".

Sutherland KD.

Oral Hyg. 1967 Mar;57(3):32-4 passim. No abstract available.

PMID:
5228444
44.

Some economics questions dentists ask.

Sutherland KD.

Oral Hyg. 1967 Jan;57(1):44-6 passim. No abstract available.

PMID:
5226064
45.

All that glitters is not the mutual fund.

Sutherland KD.

Oral Hyg. 1966 Nov;56(11):34-6 passim. No abstract available.

PMID:
5223368
46.

Does the dentist have time for real estate?

Sutherland KD.

Oral Hyg. 1966 Sep;56(9):60-1 passim. No abstract available.

PMID:
5221606
47.

Econodontics...economics in dental practice. Stock market guidance: where do you find it?

Sutherland KD.

Oral Hyg. 1966 Jul;56(7):60-2 passim. No abstract available.

PMID:
5221841
48.

Econodontics...economics in dental practice.

Sutherland KD.

Oral Hyg. 1966 Apr;56(4):54 passim. No abstract available.

PMID:
5218533
49.

Econodontics...economics in dental practice. Christmas presents in the investment field.

Sutherland KD.

Oral Hyg. 1965 Nov;55(11):60-5. No abstract available.

PMID:
5214642
50.

YOU MUST PLAN FOR YOUR POTENTIAL WIDOW.

SUTHERLAND KD.

Oral Hyg. 1965 Sep;55:58-64. No abstract available.

PMID:
14318857

Supplemental Content

Loading ...
Support Center